Sage adds titles in Therapeutic series

Share this article:
Medical publisher Sage launched two new titles in its Therapeutic Advances series: Therapeutic Advances in Drug Safety and Therapeutic Advances in Hematology.
The drug safety title will cover the safety issues pertaining to the use of drugs in different age and ethnic patient groups, adverse drug reactions, drug interactions, pharmacovigilance, risk management and other topics. The hematology title will focus on the research and practice of hematology, and will publish original research and reviews across all areas of hematology, including malignant myeloid and lymphoid disorders, red cell and platelet disorders, and other relevant topics, according to a statement on the launch.
“Rapid publication of high-quality articles from respected researchers and key opinion leaders” has been key to the success of the Therapeutic Advances series, said Gordon Mallarkey, managing editor of Therapeutic Advances in Drug Safety, in an email. “We publish articles of clinical relevance to physicians, to help them with patient management and prescribing decisions.”
Roberto Mastrorilli, Sage's head of commercial sales, said the titles are open to pharmaceutical product advertisers “wishing to target these niche audiences as part of their marketing plans.”
The two new journals, joining nine pre-existing titles in the series, are available free of charge for the first three years, to build readership.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?